Chemours Co current report, 12 February 2024

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by The Chemours Company (CC) on February 12, 2024, regarding changes to its Board of Directors. The report details the departure of a director and the appointment of a new director effective March 1, 2024.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes.

Material Changes

  • Director Departure: Sandra P. Rogers notified the Board on February 12, 2024, that she will not seek re-election at the 2024 Annual Meeting of Stockholders. Her departure is not due to any disagreement with the Company's operations, policies, or practices.
  • Director Appointment: The Board appointed Pamela F. Fletcher as a new director, effective March 1, 2024.
  • Board Composition: The Board size will increase from nine to ten members. Nine members, including Ms. Fletcher, will qualify as independent under NYSE listing standards.
  • Committee Assignments: Ms. Fletcher has been appointed to the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee.

Guidance, Outlook, and Compensation

The filing provides no financial guidance, outlook, or discussion of risks and contingencies related to operations. Regarding compensation for the new director:

  • Cash Retainer: Increased to $105,000 annually, effective January 1, 2024.
  • Equity Award: Increased to $160,000 annually, effective April 26, 2023.
  • Indemnification: Ms. Fletcher will enter into the Company's standard form of indemnification agreement.

Investor Verification Checklist

  • Verify the effective date of Pamela F. Fletcher's appointment (March 1, 2024).
  • Confirm the updated Board size (ten members) and independence status.
  • Review the attached press release (Exhibit 99.1) for additional biographical details on the new director.
  • Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.